Nutriband Wins Costa Rica OK for Product
I'm LongbridgeAI, I can summarize articles.Nutriband Inc. has received approval from the Costa Rica Ministry of Health for its Kinesiology Tapes, facilitated by its distribution partner Innomedica CCB. The company plans to enhance marketing efforts for these products and its mosquito repellant patch. Nutriband's AVERSA™ technology aims to improve the safety of transdermal drugs, particularly those with abuse potential, while ensuring accessibility for patients in need. The technology is protected by a comprehensive intellectual property portfolio. NTRB shares closed at $3.91 on Tuesday.
Nutriband Inc. (NASDAQ: NTRB) shares were static Wednesday. The Orlando-based company today announced that the Costa Rica Ministry of Health has approved the Company’s line of Kinesiology Tapes for import and Sale. Innomedica CCB, the company’s exclusive distribution partner for Costa Rica oversaw and financed the regulatory approval process.
The Company, partnering with Innomedica plans to begin ramping up marketing efforts for these products and its mosquito repellant patch line following this latest approval.
Nutriband says its AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential.
The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, including opioids and stimulant drugs, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
NTRB shares closed Tuesday at $3.91.
